Akari Therapeutics (AKTX) Receivables - Other (2015 - 2016)
Akari Therapeutics' (AKTX) quarterly Receivables - Other came in at $10717.0 in Q1 2016, down 92.45% year-on-year from $142000.0 in Q2 2015, and up 3.39% quarter-over-quarter from $10366.0 in Q4 2015.
Akari Therapeutics (AKTX) Receivables - Other (2015 - 2016) Analysis & Trends
Akari Therapeutics has disclosed Receivables - Other across 2 years of filings, most recently posting $10717.0 for Q1 2016.
- Receivables - Other for Q1 2016 came in at $10717.0, down 92.45% year-over-year; the trailing twelve-month figure through Mar 2016 was $10717.0 (down 92.45% YoY), and the FY2015 annual result was $10366.0, changed N/A from the prior year.
- Receivables - Other came in at $10717.0 for Q1 2016 at Akari Therapeutics, up from $10366.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $142000.0 in Q1 2015 to a low of $10366.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 10,717.00 |
| Mar 31, 2016 | 10,717.00 |
| Dec 31, 2015 | 10,366.00 |
| Dec 31, 2015 | 10,366.00 |
| Jun 30, 2015 | 142,000.00 |
| Jun 30, 2015 | 142,000.00 |
| Mar 31, 2015 | 142,000.00 |
| Mar 31, 2015 | 142,000.00 |